Symecko, Heather
Schnoll, Robert
Beidas, Rinad S.
Bekelman, Justin E.
Blumenthal, Daniel
Bauer, Anna-Marika
Gabriel, Peter
Boisseau, Leland
Doucette, Abigail
Powers, Jacquelyn
Cappadocia, Jacqueline
McKenna, Danielle B.
Richardville, Robert
Cuff, Lauren
Offer, Ryan
Clement, Elizabeth G.
Buttenheim, Alison M.
Asch, David A.
Rendle, Katharine A.
Shelton, Rachel C.
Fayanju, Oluwadamilola M.
Wileyto, E. Paul
Plag, Martina
Ware, Sue
Shulman, Lawrence N.
Nathanson, Katherine L.
Domchek, Susan M.
Funding for this research was provided by:
National Cancer Institute (P50CA244690)
Article History
Received: 29 August 2023
Accepted: 29 September 2023
First Online: 6 November 2023
Declarations
:
: This trial was approved by the University of Pennsylvania Institutional Review Board.
: Not applicable.
: RSB is the principal at Implementation Science & Practice, LLC. She receives royalties from Oxford University Press, consulting fees from United Behavioral Health and OptumLabs, and serves on the advisory boards for Optum Behavioral Health, AIM Youth Mental Health Foundation, and the Klingenstein Third Generation Foundation outside of the submitted work. JEB reports grants from AstraZeneca, Emerson Collective, Loxo@Lilly, and Gilead and personal fees from Reimagine Care, Healthcare Foundry, and AstraZeneca, outside the submitted work. DBM reports having been a one-time consultant for Nest Genomics. DAA is a partner at VAL Health. KAR reports receiving grants from Pfizer and AstraZeneca paid to her institution, personal fees from Merck for serving as a scientific consultant, and honoraria and travel paid as an invited speaker from MJH Life Sciences outside the submitted work. KLN reports serving on a Scientific Advisory Board for Merck, unrelated to the current study. SMD reports consulting fees from AstraZeneca and GlaxoSmithKline.